Korean Journal of Radiology

The Korean Society of Radiology (대한영상의학회)
권호 표지
DOI QR코드

DOI QR Code

Human Epidermal Growth Factor Receptor 2 Expression in Unresectable Gastric Cancers: Relationship with CT Characteristics

  • Lee, Jeong Sub (Department of Radiology, Jeju National University Hospital) ;
  • Kim, Se Hyung (Department of Radiology, Seoul National University Hospital) ;
  • Im, Seock-Ah (Department of Internal Medicine, Seoul National University Hospital) ;
  • Kim, Min A (Department of Pathology, Seoul National University Hospital) ;
  • Han, Joon Koo (Department of Radiology, Seoul National University Hospital)
  • Received : 2017.01.11
  • Accepted : 2017.03.26
  • Published : 2017.10.01
⟨ Previous Next ⟩

Abstract

Objective: To retrospectively analyze the qualitative CT features that correlate with human epidermal growth factor receptor 2 (HER2)-expression in pathologically-proven gastric cancers. Materials and Methods: A total of 181 patients with pathologically-proven unresectable gastric cancers with HER2-expression (HER2-positive [n = 32] and negative [n = 149]) were included. CT features of primary gastric and metastatic tumors were reviewed. The prevalence of each CT finding was compared in both groups. Thereafter, binary logistic regression determined the most significant differential CT features. Clinical outcomes were compared using Kaplan-Meier method. Results: HER2-postive cancers showed lower clinical T stage (21.9% vs. 8.1%; p = 0.015), hyperattenuation on portal phase (62.5% vs. 30.9%; p = 0.003), and was more frequently metastasized to the liver (62.5% vs. 32.2%; p = 0.001), than HER2-negative cancers. On binary regression analysis, hyperattenuation of the tumor (odds ratio [OR], 4.68; p < 0.001) and hepatic metastasis (OR, 4.43; p = 0.001) were significant independent factors that predict HER2-positive cancers. Median survival of HER2-positive cancers (13.7 months) was significantly longer than HER2-negative cancers (9.6 months) (p = 0.035). Conclusion: HER2-positive gastric cancers show less-advanced T stage, hyperattenuation on the portal phase, and frequently metastasize to the liver, as compared to HER2-negative cancers.

Keywords

Acknowledgement

Supported by : Radiological Research Foundation of Korea, National Research Foundation of Korea (NRF)

References

  1. Garcia M, Jemal A, Ward EM, Center MM, Hao Y, Siegel RL, et al. Global cancer facts and figures 2007. Atlanta: American Cancer Society, 2007
  2. Survival rates for stomach cancer, by stage. Cancer.org Web site. https://www.cancer.org/cancer/stomach-cancer/detection-diagnosis-staging/survival-rates.html. Accessed February 5, 2017
  3. Stomach cancer survival. Cancerresearchuk.org Web site. http://www.cancerresearchuk.org/about-cancer/stomachcancer/survival. Accessed February 5, 2017
  4. Hudis CA. Trastuzumab--mechanism of action and use in clinical practice. N Engl J Med 2007;357:39-51 https://doi.org/10.1056/NEJMra043186
  5. Piccart-Gebhart MJ, Procter M, Leyland-Jones B, Goldhirsch A, Untch M, Smith I, et al. Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. N Engl J Med 2005;353:1659-1672 https://doi.org/10.1056/NEJMoa052306
  6. Slamon DJ, Leyland-Jones B, Shak S, Fuchs H, Paton V, Bajamonde A, et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 2001;344:783-792 https://doi.org/10.1056/NEJM200103153441101
  7. Smith I, Procter M, Gelber RD, Guillaume S, Feyereislova A, Dowsett M, et al. 2-year follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer: a randomised controlled trial. Lancet 2007;369:29-36 https://doi.org/10.1016/S0140-6736(07)60028-2
  8. Tanner M, Hollmen M, Junttila TT, Kapanen AI, Tommola S, Soini Y, et al. Amplification of HER-2 in gastric carcinoma: association with topoisomerase IIalpha gene amplification, intestinal type, poor prognosis and sensitivity to trastuzumab. Ann Oncol 2005;16:273-278 https://doi.org/10.1093/annonc/mdi064
  9. Gravalos C, Jimeno A. HER2 in gastric cancer: a new prognostic factor and a novel therapeutic target. Ann Oncol 2008;19:1523-1529 https://doi.org/10.1093/annonc/mdn169
  10. Hofmann M, Stoss O, Shi D, Buttner R, van de Vijver M, Kim W, et al. Assessment of a HER2 scoring system for gastric cancer: results from a validation study. Histopathology 2008;52:797-805 https://doi.org/10.1111/j.1365-2559.2008.03028.x
  11. Bang YJ, Van Cutsem E, Feyereislova A, Chung HC, Shen L, Sawaki A, et al. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. Lancet 2010;376:687-697 https://doi.org/10.1016/S0140-6736(10)61121-X
  12. Kim SH, Kim SH, Kim MA, Shin CI, Han JK, Choi BI. CT differentiation of poorly-differentiated gastric neuroendocrine tumours from well-differentiated neuroendocrine tumours and gastric adenocarcinomas. Eur Radiol 2015;25:1946-1957 https://doi.org/10.1007/s00330-015-3600-z
  13. Kim JW, Shin SS, Heo SH, Lim HS, Lim NY, Park YK, et al. The role of three-dimensional multidetector CT gastrography in the preoperative imaging of stomach cancer: emphasis on detection and localization of the tumor. Korean J Radiol 2015;16:80-89 https://doi.org/10.3348/kjr.2015.16.1.80
  14. He J, Shi H, Zhou Z, Chen J, Guan W, Wang H, et al. Correlation between apparent diffusion coefficients and HER2 status in gastric cancers: pilot study. BMC Cancer 2015;15:749 https://doi.org/10.1186/s12885-015-1726-7
  15. Kim MA, Jung EJ, Lee HS, Lee HE, Jeon YK, Yang HK, et al. Evaluation of HER-2 gene status in gastric carcinoma using immunohistochemistry, fluorescence in situ hybridization, and real-time quantitative polymerase chain reaction. Hum Pathol 2007;38:1386-1393 https://doi.org/10.1016/j.humpath.2007.02.005
  16. Ahn HS, Kim SH, Kodera Y, Yang HK. Gastric cancer staging with radiologic imaging modalities and UICC staging system. Dig Surg 2013;30:142-149 https://doi.org/10.1159/000350881
  17. Park HS, Lee JM, Kim SH, Lee JY, Yang HK, Han JK, et al. Three-dimensional MDCT for preoperative local staging of gastric cancer using gas and water distention methods: a retrospective cohort study. AJR Am J Roentgenol 2010;195:1316-1323 https://doi.org/10.2214/AJR.10.4320
  18. Japanese Gastric Cancer Association. Japanese classification of gastric carcinoma-2nd English edition. Gastric Cancer 1998;1:10-24 https://doi.org/10.1007/PL00011681
  19. Badescu A, Georgescu CV, Vere CC, Craitoiu S, Grigore D. Correlations between Her2 oncoprotein, VEGF expression, MVD and clinicopathological parameters in gastric cancer. Rom J Morphol Embryol 2012;53:997-1005
  20. Schoppmann SF, Tamandl D, Roberts L, Jomrich G, Schoppmann A, Zwrtek R, et al. HER2/neu expression correlates with vascular endothelial growth factor-C and lymphangiogenesis in lymph node-positive breast cancer. Ann Oncol 2010;21:955-960 https://doi.org/10.1093/annonc/mdp532
  21. Park DI, Yun JW, Park JH, Oh SJ, Kim HJ, Cho YK, et al. HER-2/neu amplification is an independent prognostic factor in gastric cancer. Dig Dis Sci 2006;51:1371-1379 https://doi.org/10.1007/s10620-005-9057-1
  22. Zhang XL, Yang YS, Xu DP, Qu JH, Guo MZ, Gong Y, et al. Comparative study on overexpression of HER2/neu and HER3 in gastric cancer. World J Surg 2009;33:2112-2118 https://doi.org/10.1007/s00268-009-0142-z
  23. Lemoine NR, Jain S, Silvestre F, Lopes C, Hughes CM, McLelland E, et al. Amplification and overexpression of the EGF receptor and c-erbB-2 proto-oncogenes in human stomach cancer. Br J Cancer 1991;64:79-83 https://doi.org/10.1038/bjc.1991.243
  24. Marx AH, Tharun L, Muth J, Dancau AM, Simon R, Yekebas E, et al. HER-2 amplification is highly homogenous in gastric cancer. Hum Pathol 2009;40:769-777 https://doi.org/10.1016/j.humpath.2008.11.014

Cited by

  1. Age of Data in Contemporary Research Articles Published in Representative General Radiology Journals vol.19, pp.6, 2018, https://doi.org/10.3348/kjr.2018.19.6.1172
  2. Emerging evidence of the molecular landscape specific for hematogenous metastasis from gastric cancer vol.10, pp.6, 2017, https://doi.org/10.4251/wjgo.v10.i6.124
  3. Safety and efficacy of trastuzumab administered as a 30-min infusion in patients with HER2-positive advanced gastric cancer vol.83, pp.3, 2017, https://doi.org/10.1007/s00280-018-3753-y
  4. Relationship between CT characteristics and human epidermal growth factor receptor 2 expression in gastric cancers vol.3, pp.3, 2020, https://doi.org/10.1007/s42058-020-00041-3
  5. Mevalonate pathway as a novel target for the treatment of metastatic gastric cancer vol.20, pp.6, 2017, https://doi.org/10.3892/ol.2020.12183
  6. CT-detected extramural venous invasion is corelated with presence of lymph node metastasis and progression-free survival in gastric cancer vol.93, pp.1116, 2017, https://doi.org/10.1259/bjr.20200673
  7. Dual-Energy CT-Based Nomogram for Decoding HER2 Status in Patients With Gastric Cancer vol.216, pp.6, 2021, https://doi.org/10.2214/ajr.20.23528